Skip to main content
SpringerLink
Log in

Resistance to anti-angiogenic drugs and therapeutic options

  • Chapter
  • First Online:
Guide to Targeted Therapies: Treatment Resistance in Lung Cancer

  • 669 Accesses

Abstract

At present, bevacizumab is the only anti-angiogenic agent approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). This approval was based on the results of a large phase III study that showed improved overall survival with the combination of bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF), plus carboplatin/paclitaxel chemotherapy versus chemotherapy alone [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.

    Google Scholar 

  2. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010; 9:1525-1535.

    Google Scholar 

  3. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121:335-348.

    Google Scholar 

  4. Cascone T, Herynk MH, Xu L, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest. 2011; 121:1313-1328.

    Google Scholar 

  5. Heymach JV, Johnson BE, Prager D, et al.Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007;25:4270-4277.

    Google Scholar 

  6. Herbst RS, Sun Y, Eberhardt WE, et al.Vandetanib plus docetaxel versus docetaxel as secondline treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a doubleblind, randomised, phase 3 trial. Lancet Oncol. 2010; 11:619-626.

    Google Scholar 

  7. Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-smallcell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012 30:1114-1121.

    Google Scholar 

  8. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:1059-1066.

    Google Scholar 

  9. Reck M, Kaiser R, Mellemgaard A, et al. LUME-Lung 1 Study Group.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143-155.

    Google Scholar 

  10. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol. 2013; 31 (suppl; abstr 8034).

    Google Scholar 

  11. Garon EB, Ciuleanu TE, Arrieta O, et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-673.

    Google Scholar 

  12. Allen E, Walters IB, Hanahan D, et al. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res. 2011;17: 5299-5310.

    Google Scholar 

  13. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011; 29: 3798-3804.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Toscano Tumori, Ospedale Civile di Livorno, viale Alfieri 36, 57100, Livorno, Italy

    Federico Cappuzzo

Authors
  1. Federico Cappuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cappuzzo, F. (2015). Resistance to anti-angiogenic drugs and therapeutic options. In: Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-20741-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20741-4_6

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20740-7

  • Online ISBN: 978-3-319-20741-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation